1. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e652-735.
2.
Harskamp RE, Lopes RD, Baisden CE, et al. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 2013; 257: 824-33.
3.
Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft intervention. JACC Cardiovasc Interv 2011; 4: 831-43.
4.
Harrison RW, Aggarwal A, Ou FS, et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol 2013; 111: 178-84.
5.
Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 2004; 109: 1121-6.
6.
Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007; 99: 442-5.
7.
Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014; 20: 6212-22.
8.
Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int 2020; 20: 499.
9.
Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal 2021; 35: e23964.
10.
Candemir M, Kiziltunç E, Nurkoç S, Şahinarslan A. Relationship between systemic immune- inflammation index (SII) and the severity of stable coronary artery disease. Angiology 2021; 72: 575-81.
11.
Oztürk R, Inan D, Güngor B. Systemic immune-inflammation index is a predictor of contrast induced nephropathy in patients with ST-segment elevation myocardial infarction. Angiology 2022; 73: 125-31.
12.
Tang Y, Zeng X, Feng Y, et al. Association of systemic immune inflammation index with short-term mortality of congestive heart failure: a retrospective cohort study. Front Cardiovasc Med 2021; 8: 753133.
13.
Selcuk M, Cinar T, Saylik F, et al. Predictive value of systemic immune inflammation index for postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass grafting. Medeni Med J 2021; 36: 318-24.
14.
Tosu AR, Kalyoncuoglu M, Biter HI, et al. Prognostic value of systemic immune-inflammation index for major adverse cardiac events and mortality in severe aortic stenosis patients after TAVI. Medicina 2021; 57: 588.
15.
Vatan MB, Cakmak AC, Agac S, et al. The systemic immune-inflammation index predicts impaired myocardial perfusion and short-term mortality in ST-segment elevation myocardial infarction patients. Angiology 2023; 74: 365-73.
16.
Lesiak M, Urbanowicz TK, Olasińska-Wiśniewska A, et al. Neutrophil and lymphocyte count as predictors of the location of calcific coronary lesions in patients treated with rotational atherectomy. Adv Interv Cardiol 2023; 19: 343-50.
17.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018; 138: e618-51.
18.
Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 2010; 22: 6B-14B.
19.
Salinas P, Jimenez-Valero S, Moreno R, et al. Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem 2012; 10: 256-64.
20.
TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 312: 932-6.
21.
Van’t Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle myocardial infarction study group. Circulation 1998; 97: 2302-6.
22.
Henriques JP, Zijlstra F, Van’t Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003; 107: 2115-9.
23.
Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
24.
Zhang Q, Hu M, Sun J, Ma S. The combination of neutrophil-to-lymphocyte ratio and platelet correlation parameters in predicting the no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Scand Cardiovasc J 2020; 54: 352-7.
25.
Gürbak İ, Panç C, Şahin AA, et al. CHA2DS2- VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Cardiol Pol 2020; 78: 1129-36.
26.
Hashemi-Jazi M, Hosseini SM, Gholamrezaei A. Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 2017; 13: 221-9.
27.
Ozen Y, Bilal Ozbay M. Assessment of systemic immune-inflammation index as an independent surrogate biomarker of no-reflow phenomenon in acute coronary syndrome patients with coronary artery bypass grafting undergoing percutaneous coronary intervention of saphenous vein graft. Eur Rev Med Pharmacol Sci 2023; 27: 2394-403.
28.
Shoaib A, Kinnaird T, Curzen N, et al. Outcomes following percutaneous coronary intervention in saphenous vein grafts with and without embolic protection devices. JACC: Cardiovasc Interv 2019; 12: 2286-95.
29.
Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022; 79: e21-129.
30.
Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22: 729-39.
31.
Siminiak T, Flores NA, Sheridan DJ. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury. Eur Heart J 1995; 16: 160-70.
32.
Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 2010; 47: 2170-5.
33.
Srikanth S, Ambrose JA. Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI. Curr Cardiol Rev 2012; 8: 168-76.
34.
Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005; 45: 1638-43.
35.
Onsrud M. Influence of in vivo hydrocortisone on some human blood leucocyte sub-populations II. Effects on T cell-monocyte cooperation. Acta Pathol Microbiol Scand 1981; 89: 321-7.
36.
Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18: 487-94.
37.
Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013; 228: 203-10.
38.
Toprak C, Tabakci MM, Simsek Z, et al. Platelet/lymphocyte ratio was associated with impaired myocardial perfusion and both in-hospital and long-term adverse outcome in patients with ST-segment elevation acute myocardial infarction undergoing primary coronary intervention. Adv Interv Cardiol 2015; 11: 288-97.
39.
Kocas C, Abaci O, Arslan S, et al. The association of neutrophil to lymphocyte ratio and TIMI frame count in primary percutaneous coronary intervention. Minerva Cardioangiol 2019; 67: 471-4.
40.
Vakili H, Shirazi M, Charkhkar M, et al. Correlation of platelet- to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with thrombolysis in myocardial infarction frame count in ST-segment elevation myocardial infarction. Eur J Clin Invest 2017; 47: 322-7.
41.
Zhao B, Li J, Luo X, et al. The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: after primary percutaneous coronary intervention. Tex Heart Inst J 2011; 38: 516-22.
42.
Huang J, Zhang Q, Wang R, et al. Systemic immune inflammatory index predicts clinical outcomes for elderly patients with acute myocardial infarction receiving percutaneous coronary intervention. Med Sci Monit 2019; 25: 9690-701.
43.
Gur DO, Efe MM, Alpsoy S, et al. Systemic immune-inflammatory index as a determinant of atherosclerotic burden and high-risk patients with acute coronary syndromes. Arq Bras Cardiol 2022; 119: 382-90.